Advanced

A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure

Torp-Pedersen, Christian; Kober, Lars; Carlsen, Jan E.; Akkan, Dilek; Bruun, Niels E.; Dacoronias, Dimitri; Dickstein, Kenneth; Haghfelt, Torben; Öhlin, Hans LU and McMurray, John J. V. (2008) In European Journal of Heart Failure 10(1). p.89-95
Abstract
Background: By pre-synaptic stimulation of DA(2)-dopaminergic and alpha(2)-adrenergic receptors, nolomirole inhibits norepinephrine secretion from sympathetic nerve endings. We performed a clinical study with nolomirole in patients with heart failure (HF). Methods: The study was designed as a multicentre, double blind, parallel group trial of 5 mg b.i.d. of nolomirole (n=501) versus placebo (n=499) in patients with severe left ventricular systolic dysfunction, recently in New York Heart Association (NYHA) class III/IV. The primary endpoint was time to all cause death or hospitalisation for HF, whichever came first. The study was event driven and required 420 primary events. The study was completed as scheduled. Results: Mean age of... (More)
Background: By pre-synaptic stimulation of DA(2)-dopaminergic and alpha(2)-adrenergic receptors, nolomirole inhibits norepinephrine secretion from sympathetic nerve endings. We performed a clinical study with nolomirole in patients with heart failure (HF). Methods: The study was designed as a multicentre, double blind, parallel group trial of 5 mg b.i.d. of nolomirole (n=501) versus placebo (n=499) in patients with severe left ventricular systolic dysfunction, recently in New York Heart Association (NYHA) class III/IV. The primary endpoint was time to all cause death or hospitalisation for HF, whichever came first. The study was event driven and required 420 primary events. The study was completed as scheduled. Results: Mean age of patients was 70 years, and 73% were male. Heart rate and blood pressure were not different in the two treatment groups. There were no changes in blood pressure. There were 233 primary events in the nolomirole group versus 208 in the placebo group (p=0.1). There were 142/145 deaths and 369/374 all cause hospitalisations in the nolomirole/placebo groups. There were no differences in walking distance, quality of life or NYHA class. Conclusion: A dose of 5 mg b.i.d. of nolomirole was not beneficial (or harmful) in patients with heart failure. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
heart failure, survival, nolomirole, controlled clinical trial
in
European Journal of Heart Failure
volume
10
issue
1
pages
89 - 95
publisher
Elsevier
external identifiers
  • wos:000253038800014
  • scopus:37549062578
ISSN
1879-0844
DOI
10.1016/j.ejheart.2007.10.012
language
English
LU publication?
yes
id
80157a33-df3f-4a1b-b3d7-9c70a29d016e (old id 1198725)
date added to LUP
2008-09-10 16:29:24
date last changed
2017-08-13 03:37:21
@article{80157a33-df3f-4a1b-b3d7-9c70a29d016e,
  abstract     = {Background: By pre-synaptic stimulation of DA(2)-dopaminergic and alpha(2)-adrenergic receptors, nolomirole inhibits norepinephrine secretion from sympathetic nerve endings. We performed a clinical study with nolomirole in patients with heart failure (HF). Methods: The study was designed as a multicentre, double blind, parallel group trial of 5 mg b.i.d. of nolomirole (n=501) versus placebo (n=499) in patients with severe left ventricular systolic dysfunction, recently in New York Heart Association (NYHA) class III/IV. The primary endpoint was time to all cause death or hospitalisation for HF, whichever came first. The study was event driven and required 420 primary events. The study was completed as scheduled. Results: Mean age of patients was 70 years, and 73% were male. Heart rate and blood pressure were not different in the two treatment groups. There were no changes in blood pressure. There were 233 primary events in the nolomirole group versus 208 in the placebo group (p=0.1). There were 142/145 deaths and 369/374 all cause hospitalisations in the nolomirole/placebo groups. There were no differences in walking distance, quality of life or NYHA class. Conclusion: A dose of 5 mg b.i.d. of nolomirole was not beneficial (or harmful) in patients with heart failure.},
  author       = {Torp-Pedersen, Christian and Kober, Lars and Carlsen, Jan E. and Akkan, Dilek and Bruun, Niels E. and Dacoronias, Dimitri and Dickstein, Kenneth and Haghfelt, Torben and Öhlin, Hans and McMurray, John J. V.},
  issn         = {1879-0844},
  keyword      = {heart failure,survival,nolomirole,controlled clinical trial},
  language     = {eng},
  number       = {1},
  pages        = {89--95},
  publisher    = {Elsevier},
  series       = {European Journal of Heart Failure},
  title        = {A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure},
  url          = {http://dx.doi.org/10.1016/j.ejheart.2007.10.012},
  volume       = {10},
  year         = {2008},
}